HISUN PHARM HANGZHOU
GenericsHISUN PHARM HANGZHOU is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology.
HISUN PHARM HANGZHOU's Key Drugs
HISUN PHARM HANGZHOU's core commercial portfolio centers on IRBESARTAN AND HYDROCHLOROTHIAZIDE, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
HISUN PHARM HANGZHOU's Recent FDA Approvals
HISUN PHARM HANGZHOU secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HISUN PHARM HANGZHOU's Therapeutic Areas
HISUN PHARM HANGZHOU's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HISUN PHARM HANGZHOU's Top Competitors
HISUN PHARM HANGZHOU's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HISUN PHARM HANGZHOU Pipeline Snapshot
Active clinical trials for HISUN PHARM HANGZHOU across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IRBESARTAN AND HYDROCHLOROTHIAZIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2009-01-28
- Latest
- 2026-07-23
- Applications
- 22